![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 52, 50380-50385, December 27, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§¶,
§¶,
§,
,
, and
§
§§
From the
Gladstone Institutes of Cardiovascular
Disease and Neurological Disease, San Francisco, California 94141-9100, the § Cardiovascular Research Institute and the

Department of Pathology, University of
California, San Francisco, California 94143,
Lawrence Livermore
National Laboratory, Livermore, California 94551, and
** Allecure, Inc., Los Angeles, California 91355
Received for publication, May 17, 2002, and in revised form, October 21, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The amino-terminal domain of
apolipoprotein (apo) E4 is less susceptible to chemical and thermal
denaturation than the apoE3 and apoE2 domains. We compared the urea
denaturation curves of the 22-kDa amino-terminal domains of the apoE
isoforms at pH 7.4 and 4.0. At pH 7.4, apoE3 and apoE4 reflected an
apparent two-state denaturation. The midpoints of denaturation were 5.2 and 4.3 M urea, respectively. At pH 4.0, a pH value
known to stabilize folding intermediates, apoE4 and apoE3 displayed the
same order of denaturation but with distinct plateaus, suggesting the
presence of a stable folding intermediate. In contrast, apoE2 proved
the most stable and lacked the distinct plateau observed with the other
two isoforms and could be fitted to a two-state unfolding model.
Analysis of the curves with a three-state unfolding model (native,
intermediate, and unfolded) showed that the apoE4 folding intermediate
reached its maximal concentration ( Apolipoprotein (apo)1 E plays a key role in lipid
transport throughout the body including
the nervous system and is involved in the maintenance and repair of
neurons (1, 2). One of the common human apoE isoforms, apoE4, is a
major risk factor for Alzheimer's disease (3-5) and atherosclerosis
(6-8). ApoE4 is also associated with poor recovery from head injury
and stroke (9-11), cognitive decline associated with coronary bypass
surgery (12), increased severity of tissue damage in multiple sclerosis (13), shortening of survival after the onset of amyotrophic lateral
sclerosis (14), and a poor response to other forms of central nervous
system stress (15).
The three common isoforms of apoE (apoE2, apoE3, and apoE4) are
genetically determined and differ in cysteine and arginine content at
positions 112 and 158: apoE2 (Cys112,
Cys158), apoE3 (Cys112, Arg158),
and apoE4 (Arg112, Arg158) (16, 17). The
protein contains two distinct structural domains: a 22-kDa
amino-terminal domain and a 10-kDa carboxyl-terminal domain (18, 19).
In apoE4 and not the other isoforms, the two domains interact in a
unique manner. In apoE4, Arg112 causes
Arg61 to assume a unique conformation and interact with
Glu255 in the carboxyl-terminal domain. This novel property
of apoE4 is referred to as apoE4 domain interaction (20, 21) and was suggested to contribute to the association of apoE4 with disease (2,
21).
Previously, we demonstrated that the two domains of apoE unfold
independently for all three isoforms (19, 22) and that the 22-kDa
fragments, which contain the amino acid interchanges, differ in their
susceptibility to thermal and chemical denaturation (apoE4 < apoE3 < apoE2) (22, 23). Denaturation of apoE2 with guanidine at
neutral pH displayed two-stage cooperative unfolding, whereas apoE3 and
apoE4 displayed noncooperative unfolding that was much more prominent
with apoE4. This noncooperative unfolding of apoE4 suggested the
presence of a stable folding intermediate (22).
Folding intermediates that are both stable under certain conditions and
have nearly native structural features are referred to as molten
globules (24). Three structural features characterize the molten
globule state. First, a significant amount of secondary structure of
the native state is retained. Second, although there is considerable
loss of tertiary structure, the molten globule is structurally compact.
Third, there is internal mobility with exposure of the hydrophobic
core. Until recently, it was assumed that the molten globule was a
relatively rare state for a protein. However, there is increasing
evidence that molten globules are common and that they play a key role
in a wide variety of physiological processes, including translocation
across membranes, increased affinity for membranes, binding to
liposomes and phospholipids, protein trafficking, extracellular
secretion, and the control and regulation of the cell cycle (24, 25).
Indeed, apolipoproteins, including human apoA-I and insect
apolipophorin III, have also been reported as molten globules (26, 27).
In these cases, it was proposed that internal mobility provides
structural plasticity for binding to lipoprotein surfaces (26, 27).
In this report, we demonstrate that apoE4 forms a stable folding
intermediate more readily than apoE3 and apoE2. Using a variety of
structural tools to characterize its structure, including pepsin proteolysis, Fourier transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS), we show that this stable apoE4 folding
intermediate possesses the structural characteristics of a molten
globule. We conclude that, in addition to apoE4 domain interaction, the
propensity of apoE4 to form a molten globule may contribute to its
association with disease.
Urea Denaturation--
The 22-kDa fragments of apoE were
expressed recombinantly in bacteria and purified as described (22).
Protein (400 µg/ml) was incubated overnight at 4 °C in buffer, 1 mM dithiothreitol, and freshly deionized urea at various
concentrations. The buffer was 10 mM sodium phosphate for
experiments at pH 7.4 and 20 mM sodium acetate for
experiments at pH 4.0, which maintained the same ionic strength for
both experiments. Circular dichroism measurements were made on a Jasco
715 or Applied Biophysics Proteolysis of the 22-kDa Fragment of ApoE--
Pepsin (Sigma)
was added to the 22-kDa fragment of apoE (0.1 mg/ml, 20 nM
sodium acetate, pH 4.0) in 0, 3.75, or 4.75 M urea at a
ratio of 10:1, 250:1, or 2000:1 (apoE:pepsin, w/w), respectively, and
incubated at room temperature. At various time points, 500-µl aliquots were taken. Tris buffer and NaOH were added to inactivate pepsin, and the sample was dialyzed against 100 mM ammonium
bicarbonate to remove the urea before lyophilization of the sample. The
sample was then resuspended in a Tris-Tricine sample buffer and
analyzed by SDS-PAGE followed by transfer to a polyvinylidene fluoride membrane for amino-terminal sequencing (PerkinElmer Life
Sciences Procise protein sequencer).
Analysis of the 22-kDa Fragment of ApoE4 by Infrared
Spectroscopy--
Solution-attenuated total reflectance FTIR was
performed on the 22-kDa fragment of apoE4 (10 mg/ml, 10 mM
cacodylate, pH 4.0, with or without 3.75 M urea) as
described (29). The spectra were analyzed to estimate secondary
structural content as described (30, 31).
DLS--
Scattering data were collected at 20 °C with a
DynaPro-MS/X (Protein Solutions). Samples of the apoE4 22-kDa fragment
(0.5 mg/ml) were examined at pH 7.4 and 4.0 in the absence of urea and
at pH 4.0 in the presence of 3.75 M urea. Diffusion
coefficients were determined from scattering data with the DYNAMICS
autocorrelation analysis software (version 5.25.44, Protein Solutions).
All data could be fitted multimodally, and essentially 100% of the
scattering mass was attributed to a single low molecular mass
component. The diffusion coefficient (D) and the
hydrodynamic radius (Rh) are related by
Rh = kT/6 Turbidimetric DMPC Clearance Assay--
The kinetics of
dimyristoylphosphatidylcholine (DMPC) large multilamellar vesicle
remodeling was performed as described (33) with slight modifications.
Samples of apoE 22-kDa fragments were dialyzed into 5 mM
dithiothreitol, 20 mM sodium acetate, pH 4.0, containing
either 3.75 or 4.75 M urea at 4 °C and adjusted to a
final protein concentration of 0.5 mg/ml. A solution of DMPC (Avanti
Polar Lipids) in chloroform:methanol (1:1, v/v) was evaporated under a
stream of argon and further desiccated under reduced pressure overnight. The dried DMPC film was resuspended in 20 mM
sodium acetate, pH 4.0, containing either 3.75 or 4.75 M
urea. The concentration of DMPC was determined using an enzymatic
colorimetric assay for phospholipids (Wako Chemicals) and diluted to a
final DMPC concentration of 0.5 mg/ml. DMPC solution (400 µl) was
added to a 1-cm pathlength quartz cuvette followed by the addition of
buffer or protein solution with rapid mixing (200 µl). The turbidity
of the solution was monitored at a wavelength of 325 nm using a Beckman
DU-640 spectrophotometer. All solutions were maintained at a
temperature of 24 °C before mixing and during data collection.
To follow up on our previous guanidine denaturation studies that
suggested the presence of an apoE4 folding intermediate (22), the
22-kDa fragments of apoE3 and apoE4 were examined by urea denaturation
at pH 7.4 and pH 4.0 since low pH facilitates the formation of stable
folding intermediates (molten globules). The denaturation curves at pH
7.4 reflected an apparent two-state denaturation. The midpoints of
denaturation for the 22-kDa fragments of apoE3 and apoE4 were 5.2 and
4.3 M urea, respectively, consistent with previous results
(22) (Fig. 1A). At pH 4.0, apoE4 and apoE3 displayed the same order of denaturation (apoE4 > apoE3). However, there was a distinct plateau in the curves for both
isoforms, suggesting the presence of a stable folding intermediate
(Fig. 1B). As with guanidine denaturation, apoE2 was the
most resistant to unfolding in urea and lacked an obvious plateau
indicating that it did not form a folding intermediate (Fig.
1B.) The data in Fig. 1B were fitted to a 2-state
model (unfolded/folded, solid lines overlaying the data). The poor fits
to the apoE3 and apoE4 data further highlight the presence of stable
folding intermediates in comparison to the reasonable fit obtained for
the apoE2 data. Therefore, the data were analyzed according to a
three-state model (native/intermediate/unfolded) (28), which gave
excellent fits for the apoE3 and apoE4 isoforms (Fig. 1C)
but did not give a better fit for apoE2 than the two-state model. Fig.
2 shows the fractions of folded,
intermediate, and unfolded protein for apoE3 and apoE4, according to
the three-state model. The concentration of urea at which the folding
intermediate was at maximum concentration was 3.75 M for
the apoE4 22-kDa fragment (
90% of the mixture) at
3.75 M, whereas the apoE3 intermediate was maximal at 4.75 M (
80%). These results are consistent with apoE4 being
more susceptible to unfolding than apoE3 and apoE2 and more prone to
form a stable folding intermediate. The structure of the apoE4 folding
intermediate at pH 4.0 in 3.75 M urea was characterized
using pepsin proteolysis, Fourier transform infrared spectroscopy, and
dynamic light scattering. From these studies, we conclude that the
apoE4 folding intermediate is a single molecule with the
characteristics of a molten globule. We propose a model of the apoE4
molten globule in which the four-helix bundle of the amino-terminal
domain is partially opened, generating a slightly elongated structure
and exposing the hydrophobic core. Since molten globules have been
implicated in both normal and abnormal physiological function, the
differential abilities of the apoE isoforms to form a molten globule
may contribute to the isoform-specific effects of apoE in disease.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-180 spectropolarimeter using a
1-mm pathlength cuvette. All experiments were performed under reducing
conditions (5 mM dithiothreitol) at 25 °C. Molar ellipticity ([
]) at 220 nm was calculated from the relationship [
] = (MRW)(
220)/(10)(l)(c),
where
220 is the measured ellipticity at 220 nm in
degrees, l is the cuvette pathlength (0.1 cm), c is the protein concentration in g/ml, and the mean residue weight (MRW) was 114. The denaturation curves at pH 4.0 were analyzed according to a two- or three-state model as previously described (28).

D.
Viscosity (
) for the dilute sodium-acetate buffer was set to 1.0. The molecular mass (Mr) was estimated from the
empirical relation Mr = (Rh·k)n,
where k and n are parameters specific for the
hydrodynamic model used. For globular proteins, k = 1.68 and n = 2.34. For nonspherical proteins, the
Rh must be corrected by using the Perrin factor F determined from molecular dimensions. The apoE4 22-kDa fragment was
approximated as a prolate ellipsoid with an axial ratio of 1:2.5
(F
1.08). The pullulan model (an extended polysaccharide) was
used to estimate hydrodynamic properties for random conformations (k = 1.48, n = 1.81). The derivations
of the equations we used to calculate hydrodynamic properties are
reviewed in Ref. 32.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
90%) and 4.75 M for the
apoE3 fragment (
80%). These results demonstrate that in urea the
folding intermediate is a stable thermodynamic state, the first
criterion for a molten globule.

View larger version (18K):
[in a new window]
Fig. 1.
Urea denaturation of apoE 22-kDa
fragments. The unfolding of the apoE3 and apoE4 fragments at
various urea concentrations at pH 7.4 (A) and for the apoE2,
apoE3, and apoE4 fragments at pH 4.0 (B) was monitored by
circular dichroism. The solid lines indicate fits to a
two-state model (B) or a three-state model
(C).

View larger version (18K):
[in a new window]
Fig. 2.
Urea denaturation curves of the 22-kDa
fragments of apoE3 and apoE4 at pH 4. The curves were analyzed by
using a three-state model to determine the fraction of native
(solid line), intermediate (dashed line), and
unfolded (dotted line) structures at various urea
concentrations.
Pepsin Proteolysis--
Since proteolysis is a sensitive probe for
conformational changes in proteins (33), the apoE fragments were
subjected to limited proteolysis with pepsin at low pH with or without
urea and analyzed by SDS-PAGE and amino-terminal sequencing. In 0 M urea, there was one major fragment, which had the
amino-terminal sequence of RQQTE, which corresponds to amino acids
15-19 in apoE (Fig. 3, top
panels). This sequence is at the flexible amino terminus of the
22-kDa fragment that is not resolved in the x-ray structure (34).
Further addition of pepsin or longer digestion times did not produce
smaller cleavage products under these conditions.
|
Digestion of the apoE4 22-kDa fragment in 3.75 M urea, the
concentration at which the intermediate represents
90% of the mixture, revealed seven major bands (Fig. 3, middle panels).
Bands 1-5 had the amino-terminal sequence GS1KVE,
the same as that of recombinant apoE (it contains the novel Gly-Ser
sequence at the amino terminus) (35). Band 4 also contained a fragment
with the amino-terminal sequence 79EEQLTP. Band 6 had the
amino-terminal sequence 122VQYRG. Band 7 was rather broad
and contained three fragments (124AMLGQSTEE,
133RVRLASHLR, and 116VQYRGEVQA). Digestion of
the apoE3 22-kDa fragment in 3.75 M urea yielded the same
bands as the apoE4 digestion but with less proteolysis of the intact
apoE3 fragment (Fig. 3, middle panels).
The bands after digestion of apoE3 and apoE4 in 4.75 M urea were similar to those obtained after digestion in 3.75 M urea, but there was less difference in the extent of digestion (Fig. 3, bottom panels). This result is consistent with the prediction, based on analysis of a three-state model, that similar amounts of the intermediate states from each isoform would be present in 4.75 M urea but not in 3.75 M urea. The increased sensitivity to pepsin digestion is also consistent with an altered conformation at low pH in the presence of urea, another characteristic of a molten globule. It is also important to note that there are a limited number of exposed pepsin cleavage sites, which is consistent with a limited structural or conformational reorganization of the apoE4 intermediate without complete loss of native structure.
FTIR--
Since it is difficult to accurately estimate the
secondary structure of a protein in urea by far ultraviolet circular
dichroism due to the high absorbance of urea below 210 nm, we used a
novel FTIR method to assess the secondary structure of the intermediate in urea. This method includes the subtraction of the urea background, as well as subtraction of absorbed (partially denatured) protein (29).
The apoE4 22-kDa fragment was analyzed at pH 4.0 in the presence or
absence of 3.75 M urea (Fig.
4). ApoE4 22-kDa in 0 M urea
displayed 75%
-helix and 3%
-sheet, consistent with the
-helical content estimated by circular dichroism (18) and x-ray crystallography (34). In 3.75 M urea, apoE4 22-kDa
displayed 46%
-helix and 17%
-sheet. Thus, the intermediate
retains 61% of the native helical content, another criterion of a
molten globule. In addition, it has a significant increase in
structure, which has implications for promoting aggregation and
fibrillization.
|
DLS-- DLS was used to determine the aggregation state of the intermediate. The measured hydrodynamic radii and estimated molecular masses are summarized in Table I. The shape-corrected Mr calculated for the reference sample apoE4 22-kDa fragment at pH 7.4 with no urea was 22 kDa. At pH 4.0 (no urea), the size distribution (polydispersity) was wider, and the Rh was larger. Although the difference was not significant within the error of the experiment, it is reasonable to speculate that both the larger Rh and the greater size distribution indicate a somewhat lower stability of the apoE4 22-kDa fragment at the acidic pH, consistent with its increased tendency to form an intermediate at pH 4.0. A small widening in the flexible and dynamic helix bundle, as indicated by crystallographic studies (36), would not lead to a change in the helical content as determined from circular dichroism spectra and thus would still be compatible with a small increase in the Rh, indicating a flexing of the four-helix bundle at pH 4.0.
|
A more dramatic change was observed in the hydrodynamic behavior of the
apoE4 22-kDa fragment at pH 4.0 in 3.75 M urea.
Rh increased significantly, but the size
distribution remained narrow, indicating a well-defined intermediate
species. Assuming a large contribution of random coil conformation in
the intermediate, the Mr corresponding to the
Rh for a random coil model was estimated to be
24 kDa, consistent with a monomeric species and no evidence of
aggregation under these conditions.
Lipid Binding Abilities of the Three Isoforms--
Since molten
globules have been implicated in membrane association and phospholipid
binding (37), the relative abilities of the three isoforms to bind and
disrupt DMPC vesicles were determined at pH 4.0 in a turbidimetric
clearing assay under urea concentrations where the intermediate species
is highly populated for apoE4 and apoE3. It is important to note that
while the carboxyl-terminal domain of apoE contains the major lipid
binding determinants, the N-terminal 22-kDa domain also is capable of
binding to lipid. Previous studies have indicated that the
N-terminal 22-kDa fragment clears at approximately half the rate of
the intact protein at pH 7.4 (38). In the presence of 3.75 M urea, where the apoE4 22-kDa fragment has its maximum
population of intermediate species (
90%), apoE4 is more effective
in clearing DMPC solutions than both apoE3 and apoE2 (Fig.
5). In 4.75 M urea, where
apoE3 has its maximum population of intermediate species (
80%) and
apoE4 is close to its maximum population (
80%), apoE3 and apoE4
have a similar rate of clearance, while apoE2 lags behind. At 4.75 M urea, the relative clearance rate of apoE2 is closer to
that of apoE4 and apoE3 than at 3.75 M urea. There are two
reasons for this. First, the DMPC vesicles are smaller at 4.75 M urea than at 3.75 M, based on their relative
scattering intensities. Thus, the lipid substrate is different at the
two urea concentrations. Second, at 4.75 M urea, the apoE2
is beginning to unfold, which would be predicted to increase its
lipid-binding ability. The important point is that apoE2 still lags
behind apoE4 and apoE3, which is consistent with its greater stability
and absence of any significant concentration of a folding intermediate.
Overall, the results are consistent with the enhanced ability of the
intermediate species to remodel DMPC compared with the folded
state.
|
| |
DISCUSSION |
|---|
|
|
|---|
This study shows that the folding intermediate of apoE4 can be
stabilized and its structure characterized at pH 4.0 in 3.75 M urea. Pepsin digestion revealed that, in forming the
intermediate, apoE4 undergoes a conformational change that involves
opening of the four-helix bundle. FTIR analysis demonstrates that the intermediate retains much of its secondary structure (61%), with a
modest increase in
structure. The DLS results indicate that the
intermediate is a single molecule with a narrow polydispersity and
slightly elongated structure. These structural properties of the apoE4
intermediate are consistent with those of a molten globule. Based on
our structural characterization, we propose a model for the apoE4
molten globule (Fig. 6). The bundle is
partially open, generating a slightly elongated structure and exposing
the hydrophobic core (DLS and pepsin digestion data), and most of the
-helical structure is retained (FTIR and pepsin cleavage data). We
suggest that the helical structure is lost at the end of the helices
where it is converted to
structure or random structure, exposing
the pepsin cleavage sites
|
The largely opened conformation of the four-helix bundle in the
intermediate is similar to the conformation change of apoE when it
binds to lipid (36, 37, 39, 40). The DLS data are consistent with an
intermediate consisting of short (
20 Å) helical segments or
building blocks of the stable domain, tethered by long segments
containing random coil and
structure. Although it is difficult to
estimate accurately the hydrodynamic parameters of the intermediate
model, it is reasonable to assume that such a chain of tethered helical
segments would display very much the behavior we observe for the
folding intermediate.
The emerging view is that molten globules play an important role in many physiological processes, including translocation across membranes, increased affinity for membranes, binding to liposomes and phospholipids, protein trafficking, extracellular secretion, and the control and regulation of the cell cycle (24, 25). It has been suggested that the molten globule state is the rule rather than the exception and that it actually represents the third thermodynamic state that a protein can assume. Protein structures are not static, and it is highly likely that proteins undergo conformational changes in performing their normal functions. Thus, molten globules are ideally suited to provide this conformational flexibility. With apolipoproteins, molten globules may be particularly important in providing structural flexibility given that studies on the apoE3 22-kDa fragment and apolipophorin III reveal a correlation between faster phospholipid clearance rates and low pH and a less defined tertiary structure (27, 41).
However, protein mutations that affect molten globule formation may also adversely affect normal physiology. Such mutations may destabilize the molten globule, facilitate its formation, or trap it in this state, preventing native folding. For example, the mislocation of the cystic fibrosis transmembrane conductance regulator is suggested to involve a molten globule (24). A change in a single amino acid residue causes it to form a stable complex with the chaperone heat shock protein-70. This complex is retained in the endoplasmic reticulum, preventing it from reaching its normal location in the plasma membrane.
The greater propensity of apoE4 than apoE3 or apoE2 to form a molten globule has potential implications in lipoprotein metabolism, neuronal maintenance, and neurodegeneration, including Alzheimer's disease. ApoE transports and redistributes lipid in both the plasma and central nervous system (1), and apoE3- and apoE4-containing lipoproteins have different effects on neurite outgrowth in cultured neurons: apoE3 promotes, whereas apoE4 inhibits neurite extension (42-48). These results led to the hypothesis that apoE participates in the normal maintenance of neurons and in neuronal repair in response to central nervous system injury and that apoE3 is more efficient than apoE4 in these functions (2, 49). These differences may be directly related to how lipids are transported and delivered in an isoform-specific manner in the central nervous system, as well in the plasma. Potentially, molten globule formation could influence lipid binding properties in an isoform-specific manner, as suggested in the DMPC binding assays (Fig. 5).
In addition to apoE4 domain interaction, the apoE4 molten globule may
contribute to the apoE isoform-specific effects that have been
suggested as mechanisms to explain the association of apoE4 with
neurodegeneration. For example, the formation of an apoE4 molten
globule within lysosomes or endosomes may result in the interaction of
apoE4 with membranes and in the potential of apoE4 to translocate and
enter the cytosol where it could disrupt the cytoskeleton (44), promote
tau and neurofilament phosphorylation, and induce the formation of
intracellular neurofibrillary tangle-like inclusions (50), all features
of Alzheimer's disease pathology. Lysosomal disruption and cytoplasmic
entry may also explain the apoE4-specific enhancement of A
-induced
lysosomal leakage and apoptosis when cells are treated with the A
peptide in the presence of apoE (51). In addition, the generation of
structure in the molten globule may account for the ability of
apoE4 to promote A
amyloid fiber formation (52-54) more effectively
than apoE3 or to act as a pathological chaperone (55).
In summary, physical and structural characterization of the folding
intermediate of the apoE4 amino-terminal domain supports the conclusion
that it is a molten globule. The four-helix bundle appears to open
partially, generating a flexible species and exposing the hydrophobic
core. Since molten globules have been implicated in both the normal and
abnormal physiological functions, our working hypothesis is that the
differential abilities of the apoE isoforms to form a molten globule
also contribute to the known isoform-specific effects in disease.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. David Dolak (Protein Solutions Inc., Charlottesville, VA) for DLS data collection, Brian Auerbach for manuscript preparation, Gary Howard and Stephen Ordway for editorial assistance, Maryam Tabar for technical assistance, and Jack Hull and John Carroll for graphics. Lawrence Livermore National Laboratory is operated by the University of California for the United States Department of Energy under contract W-7405-ENG-48.
| |
FOOTNOTES |
|---|
* This work was supported in part by grant NS35939 from the National Institutes of Health (to K. H. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Both authors contributed equally to this work.
§§ To whom correspondence should be addressed: Gladstone Inst. of Cardiovascular Disease, P. O. Box 419100, San Francisco, CA 94141-9100. Tel.: 415-826-7500; Fax: 415-285-5632; E-mail: kweisgraber@gladstone.ucsf.edu.
Published, JBC Papers in Press, October 21, 2002, DOI 10.1074/jbc.M204898200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: apo, apolipoprotein; FTIR, Fourier transform infrared spectroscopy; DLS, dynamic light scattering; DMPC, dimyristoylphosphatidylcholine; Rh, hydrodynamic radius; Mr, molecular mass.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Mahley, R. W.
(1988)
Science
240,
622-630 |
| 2. | Weisgraber, K. H., and Mahley, R. W. (1996) FASEB J. 10, 1485-1494[Abstract] |
| 3. |
Strittmatter, W. J.,
Saunders, A. M.,
Schmechel, D.,
Pericak-Vance, M.,
Enghild, J.,
Salvesen, G. S.,
and Roses, A. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1977-1981 |
| 4. |
Corder, E. H.,
Saunders, A. M.,
Strittmatter, W. J.,
Schmechel, D. E.,
Gaskell, P. C.,
Small, G. W.,
Roses, A. D.,
Haines, J. L.,
and Pericak-Vance, M. A.
(1993)
Science
261,
921-923 |
| 5. |
Saunders, A. M.,
Strittmatter, W. J.,
Schmechel, D., St.,
George-Hyslop, P. H.,
Pericak-Vance, M. A.,
Joo, S. H.,
Rosi, B. L.,
Gusella, J. F.,
Crapper-MacLachlan, D. R.,
Alberts, M. J.,
Hulette, C.,
Crain, B.,
Goldgaber, D.,
and Roses, A. D.
(1993)
Neurology
43,
1467-1472 |
| 6. | Utermann, G., Hardewig, A., and Zimmer, F. (1984) Hum. Genet. 65, 237-241[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Luc, G.,
Bard, J.-M.,
Arveiler, D.,
Evans, A.,
Cambou, J.-P.,
Bingham, A.,
Amouyel, P.,
Schaffer, P.,
Ruidavets, J.-B.,
Cambien, F.,
Fruchart, J.-C.,
and Ducimetiere, P.
(1994)
Arterioscler. Thromb.
14,
1412-1419 |
| 8. | Eichner, J. E., Kuller, L. H., Orchard, T. J., Grandits, G. A., McCallum, L. M., Ferrell, R. E., and Neaton, J. D. (1993) Am. J. Cardiol. 71, 160-165[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Mayeux, R.,
Ottman, R.,
Maestre, G.,
Ngai, C.,
Tang, M.-X.,
Ginsberg, H.,
Chun, M.,
Tycko, B.,
and Shelanski, M.
(1995)
Neurology
45,
555-557 |
| 10. | Slooter, A. J. C., Tang, M.-X., van Duijn, C. M., Stern, Y., Ott, A., Bell, K., Breteler, M. M. B., Van Broeckhoven, C., Tatemichi, T. K., Tycko, B., Hofman, A., and Mayeux, R. (1997) J. Am. Med. Assoc. 277, 818-821[Abstract] |
| 11. | Teasdale, G. M., Nicoll, J. A. R., Murray, G., and Fiddes, M. (1997) Lancet 350, 1069-1071[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Tardiff, B. E.,
Newman, M. F.,
Saunders, A. M.,
Strittmatter, W. J.,
Blumenthal, J. A.,
White, W. D.,
Croughwell, N. D.,
Davis, R. D., Jr.,
Roses, A. D.,
Reves, J. G.,
and the Neurologic Outcome Research Group of the Duke Heart Center.
(1997)
Ann. Thorac. Surg.
64,
715-720 |
| 13. |
Fazekas, F.,
Strasser-Fuchs, S.,
Schmidt, H.,
Enzinger, C.,
Ropele, S.,
Lechner, A.,
Flooh, E.,
Schmidt, R.,
and Hartung, H.-P.
(2000)
J. Neurol. Neurosurg. Psychiatry
69,
25-28 |
| 14. | Drory, V. E., Birnbaum, M., Korczyn, A. D., and Chapman, J. (2001) J. Neurol. Sci. 190, 17-20[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Roses, A. D.
(1998)
Ann. N. Y. Acad. Sci.
855,
738-743 |
| 16. |
Weisgraber, K. H.,
Rall, S. C., Jr.,
and Mahley, R. W.
(1981)
J. Biol. Chem.
256,
9077-9083 |
| 17. |
Rall, S. C., Jr.,
Weisgraber, K. H.,
and Mahley, R. W.
(1982)
J. Biol. Chem.
257,
4171-4178 |
| 18. |
Aggerbeck, L. P.,
Wetterau, J. R.,
Weisgraber, K. H., Wu, C.-S. C.,
and Lindgren, F. T.
(1988)
J. Biol. Chem.
263,
6249-6258 |
| 19. |
Wetterau, J. R.,
Aggerbeck, L. P.,
Rall, S. C., Jr.,
and Weisgraber, K. H.
(1988)
J. Biol. Chem.
263,
6240-6248 |
| 20. |
Dong, L.-M.,
Wilson, C.,
Wardell, M. R.,
Simmons, T.,
Mahley, R. W.,
Weisgraber, K. H.,
and Agard, D. A.
(1994)
J. Biol. Chem.
269,
22358-22365 |
| 21. |
Dong, L.-M.,
and Weisgraber, K. H.
(1996)
J. Biol. Chem.
271,
19053-19057 |
| 22. | Morrow, J. A., Segall, M. L., Lund-Katz, S., Phillips, M. C., Knapp, M., Rupp, B., and Weisgraber, K. H. (2000) Biochemistry 39, 11657-11666[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Acharya, P., Segall, M. L., Zaiou, M., Morrow, J., Weisgraber, K. H., Phillips, M. C., Lund-Katz, S., and Snow, J. (2002) Biochim. Biophys. Acta 1584, 9-19[Medline] [Order article via Infotrieve] |
| 24. | Ptitsyn, O. B. (1995) Adv. Protein Chem. 47, 83-229[Medline] [Order article via Infotrieve] |
| 25. | Dobson, C. M. (2001) Philos. Trans. R. Soc. Lond-Biol. Sci. 356, 133-145[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Gursky, O.,
and Atkinson, D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2991-2995 |
| 27. | Weers, P. M. M., Kay, C. M., and Ryan, R. O. (2001) Biochemistry 40, 7754-7760[Medline] [Order article via Infotrieve] |
| 28. | Barrick, D., and Baldwin, R. L. (1993) Biochemistry 32, 3790-3796[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Oberg, K. A., and Fink, A. L. (1998) Anal. Biochem. 256, 92-106[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Oberg, K. A., Ruysschaert, J.-M., Azarkan, M., Smolders, N., Zerhouni, S., Wintjens, R., Amrani, A., and Looze, Y. (1998) Eur. J. Biochem. 258, 214-222[Medline] [Order article via Infotrieve] |
| 31. |
Cabiaux, V.,
Oberg, K. A.,
Pancoska, P.,
Walz, T.,
Agre, P.,
and Engel, A.
(1997)
Biophys. J.
73,
406-417 |
| 32. | Schmitz, K. S. (1990) An Introduction to Dynamic Light Scattering by Macromolecules , Academic Press, Boston |
| 33. | Spolaore, B., Bermejo, R., Zambonin, M., and Fontana, A. (2001) Biochemistry 40, 9460-9468[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Wilson, C.,
Wardell, M. R.,
Weisgraber, K. H.,
Mahley, R. W.,
and Agard, D. A.
(1991)
Science
252,
1817-1822 |
| 35. | Morrow, J. A., Arnold, K. S., and Weisgraber, K. H. (1999) Protein Expr. Purif. 16, 224-230[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Segelke, B. W., Forstner, M., Knapp, M., Trakhanov, S. D., Parkin, S., Newhouse, Y. M., Bellamy, H. D., Weisgraber, K. H., and Rupp, B. (2000) Protein Sci. 9, 886-897[Abstract] |
| 37. |
Lu, B.,
Morrow, J. A.,
and Weisgraber, K. H.
(2000)
J. Biol. Chem.
275,
20775-20781 |
| 38. |
Segall, M. L.,
Dhanasekaran, P.,
Baldwin, F.,
Anantharamaiah, G. M.,
Weisgraber, K. W.,
Phillips, M. C.,
and Lund-Katz, S.
(2002)
J. Lipid Res.
43,
1688-1700 |
| 39. | Weisgraber, K. H. (1994) Adv. Protein Chem. 45, 249-302[Medline] [Order article via Infotrieve] |
| 40. |
Fisher, C. A.,
Narayanaswami, V.,
and Ryan, R. O.
(2000)
J. Biol. Chem.
275,
33601-33606 |
| 41. | Weers, P. M. M., Narayanaswami, V., and Ryan, R. O. (2001) Eur. J. Biochem. 268, 3728-3735[Medline] [Order article via Infotrieve] |
| 42. |
DeMattos, R. B.,
Curtiss, L. K.,
and Williams, D. L.
(1998)
J. Biol. Chem.
273,
4206-4212 |
| 43. |
Nathan, B. P.,
Bellosta, S.,
Sanan, D. A.,
Weisgraber, K. H.,
Mahley, R. W.,
and Pitas, R. E.
(1994)
Science
264,
850-852 |
| 44. |
Nathan, B. P.,
Chang, K.-C.,
Bellosta, S.,
Brisch, E., Ge, N.,
Mahley, R. W.,
and Pitas, R. E.
(1995)
J. Biol. Chem.
270,
19791-19799 |
| 45. |
Holtzman, D. M.,
Pitas, R. E.,
Kilbridge, J.,
Nathan, B.,
Mahley, R. W., Bu, G.,
and Schwartz, A. L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9480-9484 |
| 46. |
Bellosta, S.,
Nathan, B. P.,
Orth, M.,
Dong, L.-M.,
Mahley, R. W.,
and Pitas, R. E.
(1995)
J. Biol. Chem.
270,
27063-27071 |
| 47. |
Fagan, A. M., Bu, G.,
Sun, Y.,
Daugherty, A.,
and Holtzman, D. M.
(1996)
J. Biol. Chem.
271,
30121-30125 |
| 48. |
Sun, Y., Wu, S., Bu, G.,
Onifade, M. K.,
Patel, S. N.,
LaDu, M. J.,
Fagan, A. M.,
and Holtzman, D. M.
(1998)
J. Neurosci.
18,
3261-3272 |
| 49. | Poirier, J. (1996) J. Psychiatry Neurosci. 21, 128-134[Medline] [Order article via Infotrieve] |
| 50. |
Huang, Y.,
Liu, X. Q.,
Wyss-Coray, T.,
Brecht, W. J.,
Sanan, D. A.,
and Mahley, R. W.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
8838-8843 |
| 51. |
Ji, Z.-S.,
Miranda, R. D.,
Newhouse, Y. M.,
Weisgraber, K. H.,
Huang, Y.,
and Mahley, R. W.
(2002)
J. Biol. Chem.
277,
21821-21828 |
| 52. | Sanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, A. D., and Strittmatter, W. J. (1994) J. Clin. Invest. 94, 860-869[Medline] [Order article via Infotrieve] |
| 53. | Ma, J., Yee, A., Brewer, H. B., Jr., Das, S., and Potter, H. (1994) Nature 372, 92-94[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Wisniewski, T., Castaño, E. M., Golabek, A., Vogel, T., and Frangione, B. (1994) Am. J. Pathol. 145, 1030-1035[Abstract] |
| 55. | Wisniewski, T., and Frangione, B. (1992) Neurosci. Lett. 135, 235-238[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
C. D. Blanchette, R. Law, W. H. Benner, J. B. Pesavento, J. A. Cappuccio, V. Walsworth, E. A. Kuhn, M. Corzett, B. A. Chromy, B. W. Segelke, et al. Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations J. Lipid Res., July 1, 2008; 49(7): 1420 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fan, S. Qiu, C. D. Overton, P. G. Yancey, L. L. Swift, W. G. Jerome, M. F. Linton, and S. Fazio Impaired Secretion of Apolipoprotein E2 from Macrophages J. Biol. Chem., May 4, 2007; 282(18): 13746 - 13753. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Chou, W.-P. Jen, Y.-H. Hsieh, M.-S. Shiao, and G.-G. Chang Structural and Functional Variations in Human Apolipoprotein E3 and E4 J. Biol. Chem., May 12, 2006; 281(19): 13333 - 13344. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Mahley, K. H. Weisgraber, and Y. Huang Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease PNAS, April 11, 2006; 103(15): 5644 - 5651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Heeren, U. Beisiegel, and T. Grewal Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 442 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-S. Ji, K. Mullendorff, I. H. Cheng, R. D. Miranda, Y. Huang, and R. W. Mahley Reactivity of Apolipoprotein E4 and Amyloid beta Peptide: LYSOSOMAL STABILITY AND NEURODEGENERATION J. Biol. Chem., February 3, 2006; 281(5): 2683 - 2692. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ye, Y. Huang, K. Mullendorff, L. Dong, G. Giedt, E. C. Meng, F. E. Cohen, I. D. Kuntz, K. H. Weisgraber, and R. W. Mahley Apolipoprotein (apo) E4 enhances amyloid {beta} peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target PNAS, December 20, 2005; 102(51): 18700 - 18705. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ramaswamy, Q. Xu, Y. Huang, and K. H. Weisgraber Effect of Domain Interaction on Apolipoprotein E Levels in Mouse Brain J. Neurosci., November 16, 2005; 25(46): 10658 - 10663. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Hatters, C. A. Peters-Libeu, and K. H. Weisgraber Engineering Conformational Destabilization into Mouse Apolipoprotein E: A MODEL FOR A UNIQUE PROPERTY OF HUMAN APOLIPOPROTEIN E4 J. Biol. Chem., July 15, 2005; 280(28): 26477 - 26482. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Lane and M. R. Farlow Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease J. Lipid Res., May 1, 2005; 46(5): 949 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
|